Polyglutamine Ataxias
Polyglutamine Ataxias - Related Videos
07:33
A Simple Composite Phenotype Scoring System for Evaluating Mouse Models of Cerebellar Ataxia
0 Views •
Cited by 415 •
2010
We describe a protocol for the rapid and sensitive quantification of disease severity in mouse models of cerebellar ataxia. Measures include hind limb clasping, ledge test, gait and kyphosis. This protocol effectively discriminates between affected and non-affected individuals, and detects the progression of affected individuals over time.
09:06
Growth Assays to Assess Polyglutamine Toxicity in Yeast
0 Views •
Cited by 3 •
2012
This manuscript describes three complementary protocols for assessing the toxicity of polyglutamine (polyQ)-expansion proteins in the yeast Saccharomyces cerevisiae. These protocols can easily be modified to monitor the toxicity of other misfolded proteins in yeast.
03:03
Fluorescent Reporter-Based Paralysis Assay: A Technique to Assess Age-Associated Progressive Formation of Polyglutamine Fluorescent Reporter and Associated Paralysis in Caenorhabditis elegans
0 Views •
2025
This video demonstrates an in vivo imaging-based assay to determine proteostasis decline due to aging. The assay uses Caenorhabditis elegans expressing polyglutamine YFP-fusion protein in body wall muscles to measure the age-associated aggregation of polyglutamine and induction of proteotoxicity, leading to paralysis.
09:23
Effect of Fluorescent Proteins on Fusion Partners Using Polyglutamine Toxicity Assays in Yeast
0 Views •
Cited by 1 •
2018
This article describes protocols to assess the effect of fluorescent proteins on the aggregation and toxicity of misfolded polyglutamine expansion for the rapid evaluation of a newly uncharacterized fluorescent protein in the context of fluorescent reporters.
08:16
Caenorhabditis elegans as a Model System for Discovering Bioactive Compounds Against Polyglutamine-Mediated Neurotoxicity
0 Views •
Cited by 7 •
2021
Here, we present a protocol to assess the neuroprotective activities of test compounds in Caenorhabditis elegans, including polyglutamine aggregation, neuronal death, and chemoavoidance behavior, as well as an exemplary integration of multiple phenotypes.
FAQs
Expanded polyglutamine tracts can destabilize proteins, encouraging misfolding and aggregation. These abnormal protein states may overwhelm or disrupt protein quality-control systems, which normally help manage damaged proteins. They can also interfere with transcription, the process that regulates gene activity. Studying both disruptions helps explain how cellular injury develops in vulnerable neurons.
Repeat length is an important modifier of clinical timing and severity: longer expanded CAG tracts are associated with differences in when symptoms begin and how severe they become. This relationship does not make every affected person identical, but it gives researchers a measurable genetic variable when comparing disease patterns and related spinocerebellar ataxias.
Selective neuronal injury remains a central neuroscience question because the expanded proteins do not damage every cell equally. Cerebellar neurons and other vulnerable neurons are especially affected as misfolding, aggregation, protein quality-control disruption, and transcription changes accumulate. Explaining this vulnerability can help connect molecular abnormalities with progressive coordination and neurological dysfunction.
Patient-derived cells provide a human-relevant system for examining disease-related cellular mechanisms, while animal models allow investigators to study those mechanisms in an organism. Used together, these approaches complement genetic testing and imaging, which help characterize disease and distinguish related spinocerebellar ataxias. Their combined use supports biomarker development and therapeutic research.
Genetic testing and imaging complement cellular and animal models in neuroscience research on polyglutamine ataxias. They contribute to defining disease mechanisms and distinguishing related spinocerebellar ataxias. Used in combination, these methods help organize disease comparisons and support the search for informative biomarkers and new treatments.
These strategies address distinct disease-related problems: the expanded repeat itself, accumulation of abnormal proteins, and injury to neurons. Researchers can therefore compare interventions aimed at different mechanisms rather than assuming one treatment will correct every defect. This framework supports biomarker development and the search for repeat-targeted, protein-clearance, and neuronal-protective treatments.